Understand the principles behind pharmaceutical quality. Connect regulations with real-world practice. Make better quality decisions.
Quality is not just about meeting a requirement.
It is about understanding why it exists—and making it work in practice.
A structured learning library for understanding pharmaceutical departments, GMP systems, manufacturing controls, and the reasoning behind regulatory expectations.
For learners, new joiners, and pharmaceutical professionals.
Explore warning letters, inspection findings, guideline updates, and the quality-system questions that regulatory developments raise.
For experienced QA professionals and quality leaders.
Industry fundamentals, GMP principles, product lifecycle and regulatory frameworks.
Understand what each function does and how GMP controls connect across a site.
Core quality systems and the evidence that demonstrates they work.
Explore process-specific risks, controls and regulatory expectations.
Use the requirements to assess controls, evidence and inspection readiness.
Translate quality-system information into sound decisions and priorities.
Short, practical articles on GMP, quality systems, audits, and regulatory expectations.
Training can address a knowledge gap, but it cannot replace investigation into why a problem occurred or what will prevent recurrence.
Good manufacturing practice should shape everyday decisions, controls, and behaviours—not only the way a site prepares for an inspection.
Calling an event human error should follow a meaningful investigation, not end it. Look at the process, tools, workload, and controls around the action.
Continue learning through connected concepts.
A source-led workspace for quality leaders: understand what regulators published, what the records actually say, and which quality-system questions may deserve attention.
A concise view of current regulatory activity. Figures remain unpopulated until connected to verified, dated source records.
Summarize new records, the facility and product type, main observations, and any published outcome.
Compare the month with prior periods, group findings by system, and highlight repeated quality risks.
Review published enforcement records and inspection observations, with direct links to original sources.
Main focus: The cited FDA letter describes issues including incoming-material identity testing, mislabeled material and supplier qualification controls. Confirm each finding in the original letter.
Quality-system lens: Material status and traceability, supplier approval, identity testing, quality-unit oversight and batch impact assessment.
Open original FDA letter ↗Main focus: FDA issued a warning letter describing significant CGMP violations under 21 CFR Parts 210 and 211. Review the complete letter for specific observations and context.
Quality-system lens: Map each cited deficiency to the relevant process, investigation, CAPA, management oversight and systemic recurrence risk.
Open original FDA letter ↗Main focus: FDA's letter addresses products labeled as sterile and concerns about manufacturing controls supporting that claim. Read the full letter to understand the precise findings and products involved.
Quality-system lens: Sterility assurance, product claims, contamination control, process design and validation.
Find the record on FDA's warning-letter page ↗Look beyond individual records to recurring themes and patterns across the available published dataset.
Identify patterns in data integrity, laboratory controls, investigations, CAPA, validation, contamination control and quality-unit oversight.
Compare published records across clearly defined periods and explain the dataset scope. Do not infer prevalence from incomplete public records.
Give quality leaders practical questions to evaluate within their own systems—without implying that another company’s finding proves the same weakness exists elsewhere.
Follow guideline revisions, regulatory announcements and changes in agency expectations.
Track new or revised guidelines, draft guidance, final guidance, GMP changes and agency announcements. Label each item by issuing authority, publication date, status and affected scope.
A short weekly scan and a deeper monthly analysis for busy quality leaders.
Weekly briefings answer “What happened this week?” Monthly reviews focus on patterns, comparisons and potential quality-system implications.
Newly published regulatory records, significant agency announcements, and one noteworthy compliance theme.
Monthly activity, recurring quality-system themes, comparisons with the prior period, and questions for quality leaders.
Interpret documented findings carefully and translate them into questions worth asking about quality systems.
Company, facility, country, date, regulator and original document.
Summarize the actual observation and preserve the source wording where needed.
Potential quality-system relevance and questions to assess internally—not automatic conclusions.
Event registration and learning resources for the pharmaceutical quality community.
Browse the types of resources that will be available to purchase. Product listings, payments, and delivery will be enabled in a later release.
Focused reference guides, checklists, and concise explainers for everyday quality work.
Topic-based modules with practical examples, knowledge checks, and application exercises.
Deeper, organised reading on GMP systems, investigations, audits, and quality leadership.
We are preparing webinars, focused training sessions, and discussions for pharmaceutical quality professionals. You can register your interest below.
A dedicated regulatory-body reference site is already being developed and will be integrated here later.
This space is reserved for the existing regulatory bodies site. The current prototype does not yet link or embed that site.
Share your details or feedback. This prototype will prepare an email for you to send.